Digest development Tapping into the digestive health market, projected to double in value from $51.7 billion in 2023 to $106.47 billion by 2032, the company also launched Pura Digest as a solution to bloating, irregularity and digestive discomfort
Tone and oxidative stress: Glutathione reduces melanin index and improves brightness in topical and oral trials, with safety confirmed in multi-center reviews
InVite's Ribose Complex is a performance-enhancing drink mix that combats stress
After the story came out, though, White House spokesperson Kush Desai stridently refuted the suggestion, writing that "this application was not for the President." Retatrutide, which was developed by drugmaker Eli Lilly, is being touted as the "next generation in the GLP-1 craze." Glucagon-like peptide-1 receptor agonists (GLP-1) are a class of medications that include semaglutide (sold as Ozempic) and tirzepatide (sold as Zepbound)
It is rarely a single number written in isolation
Clinical trial results show weight loss drug reduces the risk of heart and liver diseases in people with obesity The new study, involving world-renowned VCU expert Arun Sanyal, demonstrates semaglutide's multi-organ impact
![Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases](https://ars.els-cdn.com/content/image/1-s2.0-S0001731023008505-fx1.jpg)
